A recent study published in Endocrine highlighted the cost burden of diabetic peripheral neuropathy (DPN) in the United States. The study aimed to determine the annual cost burden of DPN.  

To estimate the cost burden of DPN in the United States, a cost-of-illness burden model was developed. To identify the most suitable epidemiologic and economic inputs, a literature review was conducted. For each model input parameter, one-way sensitivity analyses were performed to demonstrate potential variability in the estimated cost burden.  

With an estimated annual cost burden from DPN of $45,930,580,972, the estimated prevalence of DPN in the U.S. was 13,209,600 patients. It was also found that of the estimated cost burden, $30,859,424,749 was related to DPN-specific care ($26,830,282,752 for inpatient hospitalizations, $640,103,936 for prescription medications, and $2,389,038,060 for outpatient office visits), and $15,071,156,223 was from treating incident DPN complications ($2,195,956,223 for diabetic lower limb amputations and $12,875,200,000 for diabetic foot ulcers).